GenVec, Inc.

( )
GNVC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. 2.31%34.520.9%$1198.16m
JNJJohnson & Johnson 0.46%141.030.7%$1113.20m
BMYBristol-Myers Squibb Co. 0.29%59.151.0%$977.19m
MRKMerck & Co., Inc. 0.87%78.800.7%$849.39m
ABBVAbbVie, Inc. -0.25%98.891.9%$811.21m
LLYEli Lilly & Co. 0.33%163.831.1%$698.91m
AZNAstraZeneca Plc 0.92%53.811.2%$301.15m
RPRXRoyalty Pharma Plc -1.59%45.730.1%$252.67m
VXRTVaxart, Inc. -7.88%7.370.0%$224.54m
NVSNovartis AG -0.32%87.570.2%$160.39m
GSKGlaxoSmithKline Plc 0.87%41.220.2%$122.53m
RGENRepligen Corp. 1.98%126.657.2%$120.14m
NVONovo Nordisk A/S 1.05%66.370.1%$94.84m
RETAReata Pharmaceuticals, Inc. 2.56%157.853.4%$87.71m
SNYSanofi 0.68%51.620.2%$80.12m

Company Profile

GenVec, Inc. (NASDAQ: GNVC) GenVec, Inc. is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD).